Clinical Laboratory Testing Sample Clauses

Clinical Laboratory Testing. Clinical laboratory tests will be performed by the study sites’ local laboratories. Blood and urine samples will be collected, as per the SOE (Section 3) and will be prepared using standard procedures. A repeat measurement of clinical laboratory testing is permitted for eligibility determination. Other clinical laboratory retests may be permitted once in certain scenarios with CCI CCI approval. Such scenarios may include laboratory processing error, results inconsistent with subject’s historical values/medical history, or other extenuating circumstances such as a recent or intercurrent illness potentially affecting screening laboratory results. The clinical laboratory that will perform the tests will provide the reference ranges for all clinical laboratory parameters. Abnormal clinical laboratory values will be flagged as either high or low (or normal or abnormal) based on the reference ranges for each laboratory parameter. The following clinical laboratory assessments will be performed at site or laboratory appointed by site: Hematology Complete blood count (CBC) including white blood cell (WBC) count with differential count, red blood cell (RBC) count, platelet count, hematocrit, hemoglobin, red blood cell indices Coagulation Prothrombin time, partial thromboplastin time, and international normalized ratio (INR) Serum chemistry Alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total and direct), blood urea nitrogen (BUN), creatinine, lipase, serum creatine kinase, bicarbonate or total carbon dioxide, sodium, potassium, chloride, glucose, total protein, albumin, phosphate, calcium, and amylase Urinalysis Urinalysis will be performed with microscopy at indicated. Additional urinalysis may be performed as clinically indicated. It is not required to have the results from the urinalysis performed at screening before beginning study drug dosing, unless medically necessary to establish eligibility (at investigator’s discretion) Direct viral tests SARS-CoV-2 rapid test, rapid influenza diagnostic test Other analyses Female subjects: Pregnancy test (β-HCG; urine at screening and urine or serum after screening) Samples for the following laboratory tests will be sent to the sponsor or a designee for analysis: • Viral Load (as measured by RT-PCR and viral titre) • Treatment-emergent amino acid substitutions in DENV NS5 polymerase • DENV Serotype Testing • NS1 Antigen • Plasma Biomarker • Pharmacokinetic Assessment
AutoNDA by SimpleDocs
Clinical Laboratory Testing. Clinical laboratory tests will be performed by the clinical sites’ local laboratories. Blood and urine samples will be collected and prepared using standard procedures. Repeat clinical laboratory tests may be performed at the discretion of the investigator, if necessary, to evaluate inclusion and exclusion criteria or clinical laboratory abnormalities. The clinical laboratory that will perform the tests will provide the reference ranges for all clinical laboratory parameters. Abnormal clinical laboratory values will be flagged as either high or low (or normal or abnormal) based on the reference ranges for each laboratory parameter. Clinical laboratory testing will occur at screening; check-in; on Day 4; prior to discharge on Day 8 (healthy subjects) or Day 11 (hepatically impaired subjects); and at EOS. Clinical laboratory testing will occur at screening; check-in; Days 4, 8, and 12; and at EOS. The following clinical laboratory assessments will be performed for Parts 1 and 2: Hematology Absolute neutrophil count and differential, hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, leukocyte count and differential (basophils, eosinophils, lymphocytes, monocytes, and neutrophils [absolute and differential]), mean corpuscular volume, platelet count, red blood cell count, and red blood cell distribution width Coagulation International normalized ratio, partial thromboplastin time, and prothrombin time Serum chemistry Alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), blood urea nitrogen, calcium, carbon dioxide, chloride, cholesterol (total, high-density lipoprotein, and calculated low-density lipoprotein), creatinine, gamma-glutamyltransferase, globulin, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, triglycerides, and uric acid Urinalysis Bilirubin, color, glucose, ketones, leukocyte esterase, reflex microscopy (performed if dipstick is positive for protein or the blood value is 1+ or greater; and includes bacteria, casts, crystals, epithelial cells, red blood cells, and white blood cells), nitrites, occult blood, pH, protein, specific gravity, turbidity, and urobilinogen Serology Hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody types 1 and 2 (screening only) Other analyses All subjects: Urine drug screen (alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine m...

Related to Clinical Laboratory Testing

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!